A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 177-185

  Wolfson, Aaron H ^a   Brady, Mark F ^b   Rocereto, Thomas ^c   Mannel, Robert S ^d   Lee, Yi Chun ^e   Futoran, Robert J ^f   Cohn, David E ^g   Ioffe, Olga B ^h  

^a UNIVERSITY OF MIAMI   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Department of Anesthesiology   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^g Pathology Department   (United States)

^h UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Carcinosarcoma; Whole body irradiation

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 125 ANTIGEN; CISPLATIN; CREATININE; IFOSFAMIDE; MESNA; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; LYMPHEDEMA; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SALPINGOOOPHORECTOMY; SKIN MANIFESTATION; UROGENITAL TRACT DISEASE; UTERUS CARCINOMA; UTERUS SARCOMA; WHOLE BODY RADIATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYSTERECTOMY; IFOSFAMIDE; INCIDENCE; MESNA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 35348917431     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.070     Document Type: Article

References (31)

1. http://www.cancer.org/docroot/home/index.asp, November 10, 2006.
2. Curtin J.P., Kavanagh J.J., Fox H., et al. Corpus: mesenchymal tumors. In: Hoskins W.J., Perez C.A., and Young R.C. (Eds). Principles and practice of gynecologic oncology. ed 3 (2000), Lippincott, Williams & Wilkins, Philadelphia 961
3. Menczer J., Levy T., Piura B., et al. comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 97 (2005) 166-170
4. McCluggage W.G. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinosarcomas. Int J Gynecol Cancer 12 (2002) 687-690
5. WHO. Pathology and genetics of tumors of the breast and female genital organs (2003), IARC Press, Lyon
6. Sutton G., Kavanagh J., Wolfson A.H., et al. Corpus: mesenchymal tumors. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markman M., and Randall M.E. (Eds). Principles and practice of gynecologic oncology. ed 4 (2004), Lippincott, Williams & Wilkins, Philadelphia 883
7. Wolfson A.H., Wolfson D.H., Sittler S.Y., et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 52 (1994) 56-62
8. Omura G.A., Blessing J.A., Major F.J., et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 3 (1985) 1240-1245
9. Hornback N.B., Omura G.A., and Major F.J. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 12 (1986) 2127-2130
10. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early stage uterine sarcomas: a Gynecologic Oncology study. Cancer 71 (1993) 1702-1709
11. Sutton G., Kauderer J., Carson L.F., et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 96 (2005) 630-634
12. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
13. Korn E.L., and Dorey F.J. Applications of crude incidence curves. Stat Med 11 (1992) 813-829
14. Cox D.R. Regression model and life tables. J R Stat Soc B 34 (1972) 187-220
15. Blessing J.A. Design, analysis and interpretation of chemotherapy trials in gynecology cancer. In: Deppe G. (Ed). Chemotherapy of gynecology cancer. 2nd ed (1990), Alan R Liss Inc, New York, NY 63-97
16. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an EORTC Gynaecological Cancer Group study (protocol 55874) (manuscript in preparation).
17. Dusenbery K.E., Potish R.A., Argenta P.A., et al. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol 28 (2005) 295-300
18. Menczer J., Levy T., Piura B., et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 97 1 (2005) 166-170
19. Dusenbery K.E., Potish R.A., and Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol 94 (2004) 191-196
20. Callister M., Ramondetta L.M., Jhingran A., et al. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 58 (2004) 786-796
21. Gadducci A., and Romanini A. Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Gynaecol Oncol 22 (2001) 352-357
22. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol 27 (2001) 282-285
23. Knocke T.H., Weitmann H.D., Kucera H., et al. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol 73 (1999) 389-395
24. Chauveinc L., Deniaud E., Plancher C., et al. Uterine sarcomas: the Curie Institut experience: prognosis, factors and adjuvant treatment. Gynecol Oncol 72 (1999) 232-237
25. Molpus K.L., Redline-Frazier S., Reed G., et al. Postoperative pelvic irradiation in early stage uterine mixed Mullerian tumors. Gynaecol Oncol 19 (1998) 541-546
26. Gerszten K., Faul C., Kounelis S., et al. The impact of adjuvant carcinosarcoma of the uterus. Gynecol Oncol 68 (1998) 8-13
27. Chi D.S., Mychalczak B., Saigo P.E., et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 65 (1997) 493-498
28. Sutton G., Brunetto V.L., Kilgore L., et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 79 (2000) 147-153
29. Homesley H.D., Filiaci V., Markman M., et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 526-531
30. Amant F., Dreyer L., Makin J., et al. Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations. Eur J Gynaecol Oncol 22 (2001) 194-200
31. Brooks S.E., Zhan M., Cote T., et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma. Gynecol Oncol 93 (2004) 204-208